Amphastar Pharmaceuticals, Inc.AMPHNASDAQ
LOADING
|||
R&D Expense Growth Accelerating
Trending higher, above historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
11.32%
↑ 188% above average
Average (39q)
3.93%
Historical baseline
Range
High:60.67%
Low:-40.63%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 11.32% |
| Q2 2025 | -0.08% |
| Q1 2025 | 10.77% |
| Q4 2024 | -13.93% |
| Q3 2024 | 19.40% |
| Q2 2024 | 24.02% |
| Q1 2024 | -30.30% |
| Q4 2023 | 22.53% |
| Q3 2023 | -1.06% |
| Q2 2023 | -15.00% |
| Q1 2023 | 14.96% |
| Q4 2022 | -6.90% |
| Q3 2022 | -18.79% |
| Q2 2022 | 40.53% |
| Q1 2022 | -6.15% |
| Q4 2021 | 60.67% |
| Q3 2021 | -40.63% |
| Q2 2021 | 22.74% |
| Q1 2021 | -18.57% |
| Q4 2020 | 2.77% |
| Q3 2020 | 9.26% |
| Q2 2020 | 5.53% |
| Q1 2020 | -22.10% |
| Q4 2019 | 5.58% |
| Q3 2019 | 16.32% |
| Q2 2019 | 9.51% |
| Q1 2019 | -12.71% |
| Q4 2018 | 47.57% |
| Q3 2018 | -26.69% |
| Q2 2018 | 8.47% |
| Q1 2018 | 25.16% |
| Q4 2017 | 13.48% |
| Q3 2017 | -6.45% |
| Q2 2017 | -4.60% |
| Q1 2017 | -8.37% |
| Q4 2016 | 26.27% |
| Q3 2016 | -7.22% |
| Q2 2016 | 24.94% |
| Q1 2016 | -3.07% |
| Q4 2015 | -22.16% |